EpiCast Report: Healthcare-Associated Gram-Negative Infections – Epidemiology Forecast to 2026

Healthcare-associated infections (HAIs) are a major threat to patient safety. HAIs occur in hospitalized patients, and are not present at the time of admission. The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infections caused by Gram-negative bacteria are of particular public health concern, since they are at the root of approximately 30–70% of HAIs across the globe.

GlobalData epidemiologists forecast that the suspected incident cases of CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an Annual Growth Rate (AGR) of 0.60% per year over the next 10 years, from 2,592,739 cases in 2016 to 2,747,836 in 2026. In the 7MM, the US will have the highest number of suspected incident cases, with 1,311,068 in 2016, while Japan will have the lowest number of suspected incident cases, with 84,847 in 2016.

GlobalData epidemiologists forecast that the diagnosed incident cases of Gram-negative CAUTI, CLABSI, HAP/VAP, and SSI in the 7MM will grow by an AGR of 0.55% per year over the next 10 years, from 1,116,853 cases in 2016 to 1,178,754 cases in 2026. In the 7MM, the US will have the highest number of diagnosed incident cases, with 505,544 in 2016, while Japan will have the lowest number of diagnosed incident cases, with 41,245 in 2016.

GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from national nosocomial surveillance systems and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the suspected incident cases of HAIs and diagnosed incident cases of Gram-negative HAIs. In this analysis, GlobalData epidemiologists provide detailed, clinically relevant segmentations for suspected and diagnosed incident cases of Gram-negative HAIs.

Scope

The Healthcare-Associated Gram-Negative Infections EpiCast Report and EpiCast Model provide an overview of the risk factors, comorbidities, and global trends of healthcare-associated Gram-negative infections in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the suspected incident cases of healthcare-associated infections (HAIs) and diagnosed incident cases of Gram-negative HAIs in acute care, in men and women combined, ages 18 years and older, segmented by select infection sites: catheter-associated urinary tract infection (CAUTI), central line-associated blood stream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infection site-specific diagnosed incident cases of Gram-negative HAIs are further segmented by causative agent (Acinetobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa).

The Healthcare-Associated Gram-Negative Infections epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Healthcare-Associated Gram-Negative Infections EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global Gram-negative HAI market.

Quantify patient populations in the global Gram-negative HAI market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gram-negative HAI therapeutics in each of the markets covered.

Identify the percentage of suspected and diagnosed incident cases of Gram-negative HAIs by various clinical segmentations.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Healthcare-Associated Gram-Negative Infections: Executive Summary

2.1 Related Reports

2.2 ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Healthcare-Associated Gram-Negative Infections: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.3.1 US

3.3.2 5EU

3.3.3 Japan

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016–2026)

3.5.1 Suspected Incident Cases of Select HAIs

3.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs

3.5.3 Suspected Incident Cases of Select HAIs by Infection Site

3.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site

3.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of the Analysis

3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research – Key Opinion Leaders Interviewed for this Report

4.3 Primary Research – Prescriber Survey

4.4 About the Authors

4.4.1 Epidemiologist

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head and EVP of Healthcare Operations and Strategy

4.5 About GlobalData

4.6 Contact Us

4.7 Disclaimer

List of Tables

Table 1: Risk Factors for Diagnosed Incident Cases of HAIs

Table 2: 7MM, Suspected Incident Cases of Select HAIs, Ages ≥18 Years, Both Sexes, N, ...

Table 1: Risk Factors for Diagnosed Incident Cases of HAIs

Table 2: 7MM, Suspected Incident Cases of Select HAIs, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026

Table 3: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026

Table 4: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country and Specialty

List of Figures

Figure 1: 7MM, Suspected Incident Cases of Select HAIs, Both Sexes, Ages ≥18 Years, 2016 and 2026

Figure 2: 7MM, Diagnosed Incident Cases of Select ...

Figure 1: 7MM, Suspected Incident Cases of Select HAIs, Both Sexes, Ages ≥18 Years, 2016 and 2026

Figure 2: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs, Both Sexes, Ages ≥18 Years, 2016 and 2026

Figure 3: Sources Used to Forecast Suspected Incident Cases of HAIs and Suspected Incident Cases of HAIs by Infection Site

Figure 4: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs and Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site

Figure 5: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Gram-Negative HAIs by Infection Site by Causative Agent

Figure 6: 7MM, Suspected Incident Cases of Select HAIs by Infection Site, Both Sexes, Ages ≥18 Years, 2016

Figure 7: 7MM, Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site, Both Sexes, Ages ≥18 Years, 2016

Figure 8: 7MM, Diagnosed Incident Cases of Gram-Negative CAUTI by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 9: 7MM, Diagnosed Incident Cases of Gram-Negative CLABSI by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 10: 7MM, Diagnosed Incident Cases of Gram-Negative HAP/VAP by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

Figure 11: 7MM, Diagnosed Incident Cases of Gram-Negative SSI by Causative Agent, Both Sexes, Ages ≥18 Years, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports